TWI760429B - 包含倍他司汀之醫藥組成物 - Google Patents

包含倍他司汀之醫藥組成物 Download PDF

Info

Publication number
TWI760429B
TWI760429B TW107103800A TW107103800A TWI760429B TW I760429 B TWI760429 B TW I760429B TW 107103800 A TW107103800 A TW 107103800A TW 107103800 A TW107103800 A TW 107103800A TW I760429 B TWI760429 B TW I760429B
Authority
TW
Taiwan
Prior art keywords
betahistine
dose
pharmaceutical composition
administration
intranasal
Prior art date
Application number
TW107103800A
Other languages
English (en)
Chinese (zh)
Other versions
TW201831179A (zh
Inventor
克里斯多福 約翰 萊特
湯瑪士 美亞
Original Assignee
瑞士商歐托拉農股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商歐托拉農股份有限公司 filed Critical 瑞士商歐托拉農股份有限公司
Publication of TW201831179A publication Critical patent/TW201831179A/zh
Application granted granted Critical
Publication of TWI760429B publication Critical patent/TWI760429B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW107103800A 2017-02-02 2018-02-02 包含倍他司汀之醫藥組成物 TWI760429B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762453931P 2017-02-02 2017-02-02
US62/453,931 2017-02-02

Publications (2)

Publication Number Publication Date
TW201831179A TW201831179A (zh) 2018-09-01
TWI760429B true TWI760429B (zh) 2022-04-11

Family

ID=61187302

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107103800A TWI760429B (zh) 2017-02-02 2018-02-02 包含倍他司汀之醫藥組成物

Country Status (33)

Country Link
US (2) US10456386B2 (enExample)
EP (2) EP3474850B1 (enExample)
JP (3) JP7714323B2 (enExample)
KR (1) KR102653545B1 (enExample)
CN (2) CN118356397A (enExample)
AR (1) AR111699A1 (enExample)
AU (1) AU2018216970B2 (enExample)
CA (1) CA3051725A1 (enExample)
CL (1) CL2019002145A1 (enExample)
CO (1) CO2019008657A2 (enExample)
DK (2) DK3698791T3 (enExample)
EA (1) EA201991817A1 (enExample)
ES (2) ES2969301T3 (enExample)
FI (1) FI3698791T3 (enExample)
HR (2) HRP20201137T1 (enExample)
HU (2) HUE065336T2 (enExample)
IL (1) IL268353B2 (enExample)
LT (2) LT3698791T (enExample)
MA (1) MA46778B1 (enExample)
MX (1) MX381932B (enExample)
MY (1) MY196333A (enExample)
NZ (1) NZ755931A (enExample)
PH (1) PH12019501785B1 (enExample)
PL (2) PL3474850T3 (enExample)
PT (2) PT3474850T (enExample)
RS (2) RS60554B1 (enExample)
SA (1) SA519402324B1 (enExample)
SG (1) SG11201906980YA (enExample)
SI (2) SI3474850T1 (enExample)
TN (1) TN2019000220A1 (enExample)
TW (1) TWI760429B (enExample)
WO (1) WO2018141922A1 (enExample)
ZA (1) ZA201904955B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170532A1 (en) * 2017-03-22 2018-09-27 Franz, Lilian Ann Treatment method
EP4135658A1 (en) * 2020-04-14 2023-02-22 GlaxoSmithKline Consumer Healthcare Holdings (US) LLC Nasal spray formulation with moisturizing benefits
CN116209454A (zh) * 2020-04-22 2023-06-02 萨诺蒂泽研究开发公司 治疗上呼吸道感染的组合物和方法
WO2026062705A1 (en) 2024-09-23 2026-03-26 Troikaa Pharmaceuticals Limited Oromucosal liquid compositions of betahistine or its pharmaceutically acceptable salt(s) and processes for preparation thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0397025A1 (en) * 1989-05-08 1990-11-14 PRODOTTI FORMENTI S.r.l. [2-(2-pyridyl)ethyl]-methylamine salts
WO2009143572A1 (en) * 2008-05-27 2009-12-03 The University Of Melbourne Methods of treating mammals with eustachian tube dysfunctions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2397840B1 (enExample) 1977-07-22 1981-03-20 Cherqui Jean
JPH03287535A (ja) * 1990-03-31 1991-12-18 Bairon Boeki Kk プラノプロフェン水溶液
JP3203056B2 (ja) * 1992-08-13 2001-08-27 株式会社ティ・ティ・エス技術研究所 メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
JPH10139667A (ja) * 1996-11-15 1998-05-26 Yoshitomi Pharmaceut Ind Ltd 水性液剤
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
JP3555598B2 (ja) 2001-06-27 2004-08-18 株式会社村田製作所 積層型インダクタ
JP2004196676A (ja) * 2002-12-16 2004-07-15 Rohto Pharmaceut Co Ltd 点鼻剤
JP4733333B2 (ja) * 2002-12-26 2011-07-27 ライオン株式会社 点鼻剤又は洗鼻剤
ES2258694T3 (es) 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
CA2553309A1 (en) * 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
AU2006202950A1 (en) * 2004-04-22 2006-10-19 Mor Research Applications Ltd. Methods and Compositions for Weight Management
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
WO2007022345A2 (en) * 2005-08-17 2007-02-22 Fleming And Company, Pharmaceuticals Vitamin b12 nasal spray and method of use
WO2007076140A2 (en) 2005-12-23 2007-07-05 University Of Cincinnati Treatment methods employing histamine h3 receptor antagonists, including betahistine
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
BRPI0821647A2 (pt) * 2007-12-21 2015-06-16 Schering Plough Healthcare Realce da fotosestabillização de oximetazolina
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
ES2589915T3 (es) * 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
WO2016049700A1 (en) * 2014-10-03 2016-04-07 Lachesis Biosciences Pty Ltd Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0397025A1 (en) * 1989-05-08 1990-11-14 PRODOTTI FORMENTI S.r.l. [2-(2-pyridyl)ethyl]-methylamine salts
WO2009143572A1 (en) * 2008-05-27 2009-12-03 The University Of Melbourne Methods of treating mammals with eustachian tube dysfunctions

Also Published As

Publication number Publication date
SI3474850T1 (sl) 2020-09-30
EP3474850A1 (en) 2019-05-01
DK3474850T3 (da) 2020-08-03
PH12019501785A1 (en) 2020-07-06
JP2022051872A (ja) 2022-04-01
KR20190116341A (ko) 2019-10-14
HRP20201137T1 (hr) 2021-01-22
CN118356397A (zh) 2024-07-19
PL3474850T3 (pl) 2020-09-21
CN110418643A (zh) 2019-11-05
US20180214432A1 (en) 2018-08-02
WO2018141922A1 (en) 2018-08-09
US10456386B2 (en) 2019-10-29
PH12019501785B1 (en) 2024-02-28
MX381932B (es) 2025-03-13
EP3698791B1 (en) 2023-10-25
RS65099B1 (sr) 2024-02-29
SG11201906980YA (en) 2019-08-27
JP2024019731A (ja) 2024-02-09
DK3698791T3 (da) 2024-01-15
MX2019008961A (es) 2019-10-15
TN2019000220A1 (en) 2021-01-07
MY196333A (en) 2023-03-24
HUE050829T2 (hu) 2021-01-28
AU2018216970B2 (en) 2023-12-21
EP3474850B1 (en) 2020-04-22
US20200022963A1 (en) 2020-01-23
PL3698791T3 (pl) 2024-04-08
TW201831179A (zh) 2018-09-01
ZA201904955B (en) 2021-05-26
JP2020506930A (ja) 2020-03-05
AU2018216970A1 (en) 2019-08-22
ES2969301T3 (es) 2024-05-17
NZ755931A (en) 2022-07-29
LT3698791T (lt) 2024-02-12
SA519402324B1 (ar) 2023-03-16
MA46778A1 (fr) 2021-04-30
FI3698791T3 (fi) 2024-01-11
SI3698791T1 (sl) 2024-05-31
PT3698791T (pt) 2024-01-12
CA3051725A1 (en) 2018-08-09
CO2019008657A2 (es) 2020-01-17
EP3698791A1 (en) 2020-08-26
PT3474850T (pt) 2020-07-27
CL2019002145A1 (es) 2019-11-04
KR102653545B1 (ko) 2024-04-04
HUE065336T2 (hu) 2024-05-28
MA46778B1 (fr) 2022-08-31
RS60554B1 (sr) 2020-08-31
AR111699A1 (es) 2019-08-14
BR112019015687A2 (pt) 2020-04-28
IL268353B2 (en) 2023-10-01
IL268353A (en) 2019-09-26
HRP20231706T1 (hr) 2024-03-15
EA201991817A1 (ru) 2020-01-27
ES2807798T3 (es) 2021-02-24
JP7714323B2 (ja) 2025-07-29
LT3474850T (lt) 2020-08-10
IL268353B1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
US11717571B2 (en) Intranasal epinephrine formulations and methods for the treatment of disease
EP2522365B1 (en) Compositions comprising azelastine and methods of use thereof
US10736841B2 (en) Bepotastine compositions
JP2024019731A (ja) ベタヒスチンを含む鼻腔内組成物
KR102375232B1 (ko) 비강내 에피네프린 제제 및 질환의 치료 방법
US20190365728A1 (en) Pharmaceutical composition comprising betahistine
US20260007682A1 (en) Nasal compositions comprising alcaftadine
US20200268659A1 (en) Naloxone formulations for sublingual and/or buccal administration
HK40114233A (en) Intranasal composition comprising betahistine
Hasan et al. Contemporary investigation on nasal spray drug delivery system
BR112019015687B1 (pt) Composição intranasal compreendendo beta-histina e seus usos
HK40001248B (en) Intranasal composition comprising betahistine
HK40001248A (en) Intranasal composition comprising betahistine
EA041383B1 (ru) Интраназальная композиция, включающая бетагистин
CN101304769B (zh) 社会恐惧症的急性治疗